US 12,280,121 B2
Immunoconjugates and methods
Xiaojun Han, San Diego, CA (US); Suvi Tuula Marjukka Orr, San Diego, CA (US); Kevin Duane Bunker, Escondido, CA (US); Peter Qinhua Huang, San Diego, CA (US); and Kimberlee Fischer, San Diego, CA (US)
Assigned to Immunome, Inc., Bothell, WA (US)
Filed by Immunome, Inc., Bothell, WA (US)
Filed on Aug. 30, 2024, as Appl. No. 18/821,718.
Application 18/821,718 is a continuation of application No. 18/479,317, filed on Oct. 2, 2023.
Application 18/479,317 is a continuation of application No. 17/936,346, filed on Sep. 28, 2022, granted, now 11,806,405, issued on Nov. 7, 2023.
Application 17/936,346 is a continuation in part of application No. 17/812,869, filed on Jul. 15, 2022.
Claims priority of provisional application 63/267,471, filed on Feb. 2, 2022.
Claims priority of provisional application 63/203,347, filed on Jul. 19, 2021.
Prior Publication US 2024/0424121 A1, Dec. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 31/4745 (2006.01); A61K 39/00 (2006.01); A61K 47/55 (2017.01); C07K 16/18 (2006.01)
CPC A61K 47/6803 (2017.08) [A61K 31/4745 (2013.01); A61K 47/55 (2017.08); A61K 47/6851 (2017.08); C07K 16/18 (2013.01); A61K 2039/505 (2013.01)] 12 Claims
 
1. An immunoconjugate represented by:

OG Complex Work Unit Chemistry
wherein Ab is an antibody or an antigen-binding fragment thereof, and n is an integer from 1 to 10.